Fig. 1: T-cell-inflamed head and neck squamous cell carcinoma are enriched in cDC expressing PD-L1high and ICOSLlow/neg. | Nature Communications

Fig. 1: T-cell-inflamed head and neck squamous cell carcinoma are enriched in cDC expressing PD-L1high and ICOSLlow/neg.

From: PD-L1 and ICOSL discriminate human Secretory and Helper dendritic cells in cancer, allergy and autoimmunity

Fig. 1

Phenotypic characterization of 22 human head and neck squamous cell carcinoma (HNSCC) primary tumor-infiltrating cells. A Multicolor flow cytometry (FC) analysis scheme. B Myeloid cell panel gating strategy for the CD45+CD3−CD16−CD19− (Lin) compartment (initial gates in Supplementary Fig. 2A). MMAC monocytes and macrophages, DN DC/MMAC double negative population. C Percentage of CD3-positive cells among live cells, bar represents median. D Heatmap representing the normalized values of the parameters (columns) with a Spearman correlation coefficient (r) over 0.3 (left) or under −0.3 (right) for the 22 tumors (rows) ordered from top to bottom by decreasing CD3/Live normalized value. Dark gray cells represent missing values. T T cells, pDC plasmacytoid DC, DR HLA-DR, Neutrophils_e neutrophils enriched, DN MAIT, NKT, T CD4−CD8− MAIT, Natural Killer T, and T cells, respectively. E Representative staining of PD-L1 (left), ICOSL (center), and PD-L1 versus ICOSL (right) in CD11c+DR+ cells in a CD3 high tumor (top), CD3 low tumor (middle) from the cohort in D, and blood from a healthy donor (bottom); the percentage of positive cells was measured based on antibody (Ab) as compared to isotype (Iso).

Back to article page